BSG and hepatocellular carcinoma: This mA HAb18 modification enhances the cytotoxic potency of the CD147 monoclonal antibody by 10 to 20 times in HCC cells with significant in vivo tumor growth arrest (p<0.01) and was well tolerated without adverse events in animal studies (111).